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In Brief
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expansion proteins (polyAla, polySer,
polyLeu, and polyCys). These repeat-
associated non-ATG (RAN) proteins are
expressed in a length-dependent manner
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affected in HD.
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Huntington disease (HD) is caused by a CAG,CTG
expansion in the huntingtin (HTT) gene. While
most research has focused on the HTT polyGln-
expansion protein, we demonstrate that four addi-
tional, novel, homopolymeric expansion proteins
(polyAla, polySer, polyLeu, and polyCys) accumu-
late in HD human brains. These sense and antisense
repeat-associated non-ATG (RAN) translation pro-
teins accumulate most abundantly in brain regions
with neuronal loss, microglial activation and
apoptosis, including caudate/putamen, white mat-
ter, and, in juvenile-onset cases, also the cere-
bellum. RAN protein accumulation and aggregation
are length dependent, and individual RAN proteins
are toxic to neural cells independent of RNA effects.
These data suggest RAN proteins contribute to HD
and that therapeutic strategies targeting both sense
and antisense genes may be required for efficacy
in HD patients. This is the first demonstration that
RAN proteins are expressed across an expansion
located in an open reading frame and suggests
RAN translation may also contribute to other poly-
glutamine diseases.
INTRODUCTION
Huntington disease (HD) is a progressive neurodegenerative dis-
order characterized by severe movement, cognitive, and behav-ioral changes caused by a CAG,CTG expansion in theHTT gene
(Orr and Zoghbi, 2007). Upon translation, this expansion muta-
tion results in the production of a mutant huntingtin protein
(HTT) with an expanded polyGln repeat tract. HD is one of nine
neurologic diseases caused by CAG expansion mutations that
encode broadly expressed proteins containing expanded poly-
Gln tracts. While there is substantial evidence that mutant
HTT and other polyGln expansion proteins are toxic and
contribute to disease, the differential vulnerability of specific
brain regions is not yet understood. In HD, expansions >40 re-
peats are fully penetrant, and longer alleles are associated with
earlier, sometimes juvenile, onset and increased disease
severity. While nearly all research into the molecular mecha-
nisms of HD has focused on the downstream effects of the
mutant HTT protein, CUG HD-antisense transcripts (Chung
et al., 2011) and CAG microRNAs have also been reported and
may play a role in disease (Ban˜ez-Coronel et al., 2012). The dis-
covery of repeat associated non-ATG (RAN) translation (Zu et al.,
2011) in spinocerebellar ataxia type 8 (SCA8) raises the possibil-
ity that sense and antisense mutant proteins may be expressed
from the HD CAG,CTG expansion mutation.
RAN translation has now been reported in several diseases
with non-coding expansion mutations (Ash et al., 2013;
Mori et al., 2013; Todd et al., 2013; Zu et al., 2011, 2013).
It is not yet clear if RAN translation can occur across expan-
sion mutations located in an open reading frame (ORF), such
as the polyglutamine diseases. In these cases, RAN could be
limited because these repeats are generally shorter than non-
coding expansions and because the position of these
repeats in conventional ORFs may inhibit RAN translation. To
test if RAN translation can occur in a polyglutamine disease,
we examined one of the most prevalent polyglutamine disor-
ders, HD.Neuron 88, 667–677, November 18, 2015 ª2015 Elsevier Inc. 667
RESULTS
RAN Proteins Accumulate in Cells Expressing Mutant
HTT and in Human HD Brains
To test if RAN translation can occur across the HTT ORF
in transfected cells,wegenerateda seriesofminigenescontaining
HTT exon 1 with expansion mutations (Figure 1A). Immunoblots
and immunofluorescence (IF) performed on transiently trans-
fected HEK293T cells demonstrate that RAN translation occurs
across a CAGEXP located in the ATG-initiated ORF of an HTT-
exon 1minigene andproducespolyAla andpolySer RANproteins.
Additionally, constructs lacking the ATGdemonstrate that anATG
initiation codon is not required for expression of the polyGln,
polyAla, or polySer expansion proteins (Figures 1B and S1Aa).
Furthermore, polyAla and polySer are expressed at similar levels
with andwithout anATG initiationcodon in thepolyGln frame, indi-
cating that frameshifting from an AUG-initiated polyGln reading
frame is not required for polyAla or polySer expression in these
minigenes. In contrast, (CAG)23 and non-hairpin-forming (CAA)80
constructs produce ATG-initiated polyGln but not RAN polyAla
or polySer proteins (Figures 1B and S1Ab). In summary, these
data show that HTT exon-1 (CAG)80 transcripts can express
RAN proteins in all three reading frames in transfected cells.
Because frameshifting has been previously reported in HD
(Davies and Rubinsztein, 2006) and SCA3 (Gaspar et al., 2000;
Toulouse et al., 2005), we performed a second series of experi-
ments to test if frame-shifted products, which initiate at the AUG
in the glutamine frame, can also produce hybrid polyGln/polyAla
and polyGln/polySer proteins. We transfected cells using a
modified HD exon 1 minigene with a 50 V5 tag in the polyGln
frame and three C-terminal epitope tags to label proteins trans-
lated in each of the three reading frames (Figure S1Ac). Immuno-
precipitations using antibodies against the C-terminal tags in the
polyAla (a-HA) and polySer (a-Flag) frames followed by immuno-
blotting using the N-terminal and C-terminal tags shows that the
polyAla and polySer proteins do not contain the N-terminal V5
tag in the ATG-initiated polyGln frame (Figure S1Ac).
To test if RAN proteins are expressed in vivo, a panel of
polyclonal antibodies against the predicted C-terminal regions
available for four of the five possible novel RAN proteins was
generated (Figure 1C). The specificities of these antibodies,
which recognize the putative polyAla (GCA), polySer (AGC),
polyLeu (CUG), and polyCys (UGC) proteins, were demon-
strated in transfected cells (Figure S1B). Next, we tested if
HD-RAN proteins could be detected by immunohistochemistry
(IHC) in the striatum, a prominently affected brain region in
HD. We found striking positive staining using all four HD-RAN
antibodies: a-Ala-Ct, a-Ser-Ct, a-Leu-Ct, and a-Cys-Ct (Fig-
ure 1D; Table 1) in HD but not HDL2 or control samples. No
similar staining was seen with the corresponding pre-immune
control sera for the various antibodies (Figure 1D). Protein blot
analyses of insoluble lysates from human HD frontal cortex pro-
vide additional evidence that RAN proteins accumulate in HD
but not control brains (Figure 1E). These results show that,
in addition to the HTT polyGln expansion protein, the HD
CAG,CTG expansion mutation also expresses four novel HD-
RAN proteins and that these proteins are expressed from both
sense and antisense transcripts.668 Neuron 88, 667–677, November 18, 2015 ª2015 Elsevier Inc.RAN Proteins Accumulate in Specific Striatal Regions
To explore areas of the striatum that are predominantly affected
in HD (Figure 2A), we performed a series of IHC experiments us-
ing the HD-RAN protein antibodies in HD cases with Vonsattel
grade II-IV. These experiments show strong HD-RAN protein
staining in the caudate and putamen of the striatum, two regions
severely affected in HD (Figure 2B, 2D–2G, and S2A–S2D;
Table 1). Both nuclear and cytoplasmic RAN protein staining
was found in neurons and can appear as diffuse staining or as
punctate aggregates. Additional staining was seen in astrocytes
and microglia in the caudate and putamen. HD-RAN antibodies
also show consistently strong nuclear staining in thewhitematter
bundle regions of the caudate and putamen, a region containing
astrocytes and oligodendrocytes (Figure 2B, 2D–2G, and S2A–
S2D; Table 1). In contrast, HD-RAN staining is only rarely
observed in the internal capsule, a white matter structure con-
taining both ascending and descending axons that separate
the caudate nucleus from the putamen, and which is relatively
preserved in HD. While the pattern of sense and antisense
RAN protein staining across the caudate-putamen is strikingly
similar, the pattern of staining using the 1C2 or EM48 antibodies
to detect the expanded HTT polyGln protein was distinct. First,
although 1C2/EM48 staining of neurons in the caudate and
putamen is present and detects previously reported nuclear
aggregates, positive cells are much less frequent (Figures 2B,
2C, and S2E). A second notable difference is that polyGln
aggregates detected by1C2 or EM48 are not detected in regions
with the most intense RAN-protein staining, the white matter
bundles of the caudate and putamen (Figures 2B, 2C, and S2E).
RAN Proteins Accumulate in Regions with
Neuroinflammatory Changes
Neuroinflammatory changes including an increase in microglial
cells have been reported in HD and correlate with neuronal loss.
To test if neuroinflammatory changes are found in areas that are
RAN positive, we stained serial sections of the human autopsy
material with the IBA1 antibody that recognizes microglia. RAN-
positive regions of the caudate and putamen were also strongly
positive for IBA1, and similar to the HD-RAN staining, the most
intense IBA1 staining was seen in the RAN-positive white matter
bundles (Figures 2B, 2H, and S2F). Next, we performed a double
labeling experiment in whichRAN-positive cells were labeledwith
a brown chromogen using a mixture of the a-polyAla-Ct, a-poly-
Ser-Ct, a-polyLeu-Ct, and a-polyCys-Ct antibodies, and micro-
glia/macrophages were labeled using the a-IBA1 antibody with
a blue chromogen. The IBA1/RAN double labeling experiments
show that microglia and RAN-positive cells are distributed
in three patterns in the various regions of striatum: (1) RAN-nega-
tive microglia, (2) RAN-negative microglia in close proximity to a
RAN-positive cell, and (3) RAN-positive microglia (Figure 2J).
RAN Proteins Accumulate in Regions Undergoing Cell
Death
Because caspase-3 is a prominent marker of cell death in HD,
we also stained serial sections to determine if RAN-positive
areas are caspase-3 positive. Caspase-3-positive cells were
found in both the caudate and putamen and also within the
caudate and putamen white matter bundles, which are positive
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Figure 1. RAN Translation in HD
(A) CAG andCAAHTT-exon1minigeneswith a 63 STOP codon cassette (two stops in each frame) upstream ofHTT exon 1 andC-terminal epitope tags in each of
the three reading frames.
(B) Immunoblots of HEK293T cells show polyGln expression from all +ATG-constructs and RAN polyGln, polyAla and polySer proteins from (CAG)80 but not
(CAG)23 or non-hairpin-forming (CAA)80 expansions.
(C) Schematic diagram of putative HD-RAN proteins. C-terminal regions used to generate peptide for HD-RAN polyclonal antibodies are underlined.
(D) IHC staining of human autopsy tissue shows positive staining (red) for sense (polyAla and polySer) and antisense (polyCys and polyLeu) RAN proteins in HD ([De]–
[Dh]) but not HDL2 ([Di]–[Dl]), control ([Da]–[Dd]) or preimmune ([Dm]–[Dp]) controls. Red, positive staining; blue, nuclear counterstain.
(E) Protein blots showing RAN proteins detected from the insoluble fraction of HD but not control frontal cortex lysates. See also Figures S1A and S1B. HMW, high
molecular weight.
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Table 1. Summary of RAN Protein Staining in HD Cases and Controls
Case Age Sex/Race Repeat PMD Vonsattel Grade Striatum Frontal Cortex Cerebellum
CTRL 1 40 M/W 6   
2 56 F/W 13   
3 45 F/W 20   
4 57 M/W   
HD 1 47 M/W N/A 30 2 ++ ++ ++
2 57 M/W N/A 26 2 ++ + ++
3 60 F/W N/A 24 3 +++ + +
4 57 F/W N/A 9.5 3 +++ + +
5 52 M/B 49 24 3/4 +++ ++ +
6 41 M/W 52 8 4 +++ + +
7 46 F/W N/A 7 4 +++ + +
JHD 1 8 F/ >100*  +++ ++ ++++
2 8 M/B 100*  3 ++++ +++ ++
3 27 M/W 69 22 4 +++ ++ ++
4 23 F/B 76 14 4 ++++ ++ +
5 23 F/W 64 13 4 +++ ++ ++
HDL2 1 58 M/B 11.5 4   
2 41 F/B 3 3   
SCA8 80 F NA NA 
RAN staining: , negative; +, low-intensity staining; ++, moderate intensity; +++, frequent and intense; ++++, highly frequent positive cells with high
intensity staining. CTRL, control; HD, Huntington disease; JHD, juvenile Huntington disease; HDL2, Huntington disease like-2; SCA-8, Spinocerebellar
ataxia type 8; N/A, not available; *, repeat length estimated from autopsy brains; M, male; F, female.for HD-RAN proteins but negative for the polyGln HTT protein
(Figure S2G). Additional double labeling experiments show
40%–60% of cells positive for active caspase-3 are also positive
for one or more RAN proteins in the caudate, caudate white-
matter bundles, putamen white matter bundles, and putamen
(Figure 2K). These studies show RAN-positive cells are found
in regions with markers of cell death.
HD-RAN Proteins in Frontal Cortex and Cerebellum
Since neurodegenerative changes in HD also occur in additional
regions of the brain including the frontal cortex and the cere-
bellum, we tested these regions for RAN protein staining.
Neuropathology in the frontal cortex is well established in HD,
with cortical degeneration, neuronal loss in all layers, and
increased density of large glial cells (Bates et al., 2014). Addi-
tionally, variable involvement of the cerebellum has recently
been reported in HD (Bates et al., 2014; Ru¨b et al., 2013).
In the frontal cortex, positive staining for the four HD-RAN
proteins was found in clustered patches, with the most promi-
nent staining found in cortical layers II and III in HD but not con-
trols. Nuclear staining for HD-Ala, HD-Ser, HD-Leu, and HD-Cys
was also found in HD cortical white matter (Figures 3A and S3A–
S3D; Table 1). In the cerebellum, HD patients but not controls
show RAN-protein staining (Figures 3B and S3A–S3D; Table
1). Staining is found in the molecular and granule cell layers
and in areas of Bergmann-glial proliferation surrounding the
Purkinje cells. Staining of neurons in both the cortex and cere-
bellum was nuclear, cytoplasmic, or perinuclear and was diffuse
or localized to dense aggregates. In contrast, staining in cere-670 Neuron 88, 667–677, November 18, 2015 ª2015 Elsevier Inc.bral and cerebellar white matter showed intense nuclear
localization.
In summary, while RAN protein staining in the cortex and cer-
ebellum is easily detected, staining in the striatum was consis-
tently more intense. IHC using the 1C2 antibody to detect
expanded polyGln protein also showed nuclear staining in the
neuronal layers of the frontal cortex (Figures 3A and S3E), but
no staining was evident in the white matter regions of the frontal
cortex or the cerebellum (Figures 3B and S3E).
HD-RAN Proteins in N171-82Q HD Mice
Next, we tested if HD-RANproteins can be expressed in amouse
model of HD. We chose the N171-82Q HD mice (Schilling et al.,
1999) for analysis because the transgene contains both a RAN-
competent CAG expansion mutation and human flanking se-
quences that allow detection with the C-terminal polySer and
polyAla antibodies that we developed. Figure 3C shows that,
similar to humanHD autopsy tissue, HD-polyAla andHD-polySer
are also detected in this mousemodel by IHC (Figure 3C). It is not
known at this time if antisense transcripts or antisense RAN pro-
teins are expressed in these mice. Our findings of sense RAN
proteins in these mice provide proof-of-principle evidence that
RAN proteins can be expressed in mouse models of HD and
that mice may be a useful tool for understanding the impact of
HD-RAN proteins on disease.
In summary, RAN proteins accumulate in two additional
affected brain regions, the frontal cortex and cerebellum. Addi-
tionally, prominent RAN-positive staining was observed in the
absence of detectable polyGln staining in white matter regions.
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Figure 2. HD-RAN Proteins in Striatum
(A) Control and HD brain showing striatal sub-regions with summary of staining.
(B) Quantification of IHC-positive cells for a-Gln, a-RAN, and IBA1 staining ± SEM in caudate nucleus.
(C–I) IHC of striatal sub-sections fromHD brains using (C) a-Gln antibody (1C2), ([D]–[G]) a-RAN antibodies, (H) a-IBA1 for microglia, and (I) a-active caspase-3 for
cell death. (A)–(I): red, positive staining; blue, nuclear counterstain.
(J) Double staining for RAN protein cocktail using mixture of all four anti-RAN antibodies (brown) plus anti-IBA1 antibody to label microglia with quantitation
(± SEM) of single-, double-labeled, and IBA1 cells that are in close proximity to RAN-positive cells.
(K) Double staining for RAN protein cocktail usingmixture of all anti-RAN antibodies (brown) plus anti-caspase-3 antibody to label apoptotic cells with quantitation
of the percent active Caspase-3-positive cells that are also positive for RAN proteins. See also Figure S2. Cau-WMB, caudate white matter bundles; Int-Cap,
internal capsule; Put-WMB, putamen white matter bundles.This latter observation suggests that RAN proteins play a role in
white matter abnormalities previously described in HD, such as
gliosis and white matter changes detected by DTI/MRI imaging
(Bohanna et al., 2011; Fennema-Notestine et al., 2004; Paulsen
et al., 2010; Reading et al., 2005).
RAN-Protein Accumulation and Aggregation Are Length
Dependent
Longer CAG expansions are associated with earlier onset and
increased severity in HD and other polyGln expansion disorders
(Ross et al., 1999). To investigate the effects of repeat length on
HD-RAN proteins, we developed a series of HTT-exon-1 mini-
genes with repeats ranging in length from 23 to 80 CAGs (Fig-
ure 4A). Transient transfections were performed and cell lysates
examined for the accumulation of ATG-initiated polyGln and
HD-RAN polyAla and polySer proteins. As expected, ATG-initi-
ated polyGln proteins are expressed and accumulate at all repeat
lengths (23–80 repeats) (Figures 4B, 4C, and S4A). In contrast,RAN-protein accumulation and aggregation is length dependent.
For example, protein blotting and IF show HD-polyAla RAN pro-
teins accumulate in cells expressing CAG repeatsR52 but not at
repeats%45. In the polySer frame, RAN protein accumulation is
evident atR35 repeats, and as the repeats get longer, RAN-poly-
Ser shifts from being in the soluble (35–40 repeats) to the insol-
uble fraction (45–80 repeats) by protein blot (Figure 4B). Similarly,
in transfected cells, polySer staining changes from a diffuse
pattern (35–40 repeats) to a progressively more punctate, almost
pin-like staining pattern forming granular cytoplasmic inclusions
(45–80 repeats) (Figures 4C and S4A). In summary, the selective
accumulation of RAN polyAla and punctate polySer proteins in
this in vitro system occurs at repeat lengths typically associated
with early-onset and juvenile cases of HD.
HD-RAN Proteins Decrease Cell Survival In Vitro
The discovery of HD-RAN proteins in caspase-3-positive brain
regions strongly suggests that RAN proteins are toxic. ToNeuron 88, 667–677, November 18, 2015 ª2015 Elsevier Inc. 671
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Figure 3. HD-RAN Proteins in Human Frontal Cortex
and Cerebellum and HD Mice
(A and B) IHC staining of control and HD gray and white
matter of (A) frontal cortex and (B) cerebellum using a-RAN
and a-Gln (1C2) antibodies show punctate nuclear and
cytoplasmic staining with a-polyAla, a-polySer, a-polyLeu,
and a-polyCys. GCL, granule cell layer; PCL, Purkinje-cell
layer; ML, molecular layer. Staining of the cortex and cere-
bellum in adult-onset HD cases is variable. IHC images and
quantification of percent positive cells represent typical
positive regions.
(C) IHC staining of indicated brain regions in N171-82Q and
control mice using the a-polyAla, a-polySer. Red, positive
staining; blue, nuclear counterstain. See also Figures S3A–
S3E.
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Figure 4. Length-Dependent RAN Protein
Expression, Aggregation, and Toxicity
(A) CAG and CAA HTT-exon1 minigenes.
(B and C) (B) Immunoblots and (C) IF of HEK293T
cells after transfection with indicated constructs.
(D) Transfected minigenes (top) containing non-
hairpin-forming alternative codons in the repeat
region for polyGln90 (CAA), polySer90 (TCC-TCT),
polyLeu90 (CTT-CTC), and polyCys90 (TGT) con-
structs. Because non-haipin forming codon sub-
stitutions encoding polyAla were not available,
polyAla was expressed by a +ATG-GCA construct
using a slightly longer repeat tract of 105 repeats.
(E and F) LDH assays of SH-SY5Y and T98 cells
expressing polyGln and individual HD-RAN pro-
teins 42 hr post-transfection. Values equal percent
of cell death ± SEM (n = 5; *p < 0.05, **p < 0.01,
and ***p < 0.001). See also Figures S4A–S4F.examine the effect of each individual RAN protein independently
of RNA-mediated effects, we generated polyGln, polySer,
polyLeu, and polyCys minigenes using alternative codons to
prevent RNA hairpin formation and RAN translation (Zu et al.,
2011). Because non-hairpin forming codons are not available
for polyAla, we increased polyAla expression relative to polyGln
and polySer by including an ATG-initiation codon in the polyAla
reading frame. ATG-initiated polyAla was generated with a
GCA expansion (Figure 4D). All the minigenes expressed pro-
teins with the repeat expansion and the complete C-terminal re-
gion for each protein.
SH-SY5Y neuronal and T98 glial cells transfected with these
constructs showed a significant increase in cell death compared
to cells expressing a short repeat. HD-RAN polySer, polyLeu,
and polyCys proteins are equally or more toxic than polyGln
alone. The transfection with the polyAla construct, which ex-
presses high polyAla levels, but also low levels of polyGln and
polySer, dramatically increased cell death (Figures 4E, 4F, and
S4C). In contrast, toxic effects of these proteins were less robust
or not found in transfectedHEK293T cells at 18, 24, or 42 hr post-Neuron 88, 667–677, Ntransfection (Figures S4B, S4C, and S4F),
suggesting that the vulnerability to HD-
RAN proteins is cell type specific. Taken
together, these data demonstrate that
the expression of individual polySer, poly-
Leu, and polyCys HD-RAN proteins using
non-hairpin-forming alternative codons
increases cell death in neuronal and glial
cells.
HD-RAN Proteins Accumulate in
Severely Affected Cerebellar
Regions in Juvenile HD
In adult-onset HD, there is a predictable
disease progression that first, and most
severely, affects the caudate/putamen
followed by the frontal cortex and other
brain regions. In contrast, disease pro-
gression in juvenile-onset cases shows amore widespread pathology, with some patients showing severe
involvement of the caudate and putamen while others show rela-
tive sparing of this region but severe atrophy of the cortex or cer-
ebellum (Figure 5A) (Bates et al., 2014). Given that RAN protein
expression increases with repeat length, we tested if RAN pro-
tein staining is more prominent in juvenile HD cases and if
severely affected regions show increased RAN protein accumu-
lation. To explore this question, we analyzed autopsy tissue from
five juvenile-onset cases. All five cases showed increased fre-
quency and more intense staining for all four RAN proteins in
striatum, frontal cortex, and cerebellum (Table 1). Two of these
cases, which came to autopsy at 8 years of age with repeats
greater than 100, showed marked cerebellar atrophy with abun-
dant RAN protein staining in all layers of the cerebellum (Figures
5B, 5C, and S5A; Tables 1 and 2).
In themost severely affected juvenileHDcase (JHD-1), the cer-
ebellum showedmore intense RANpolySer and polyCys staining
compared to adult HD (Table 1; Figure S5A) with JHD showing
ubiquitous, densely reactive, often punctate nuclear or perinu-
clear staining in regions throughout the cerebellum. Positiveovember 18, 2015 ª2015 Elsevier Inc. 673
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Figure 5. Increased RAN Protein Staining in
Juvenile HD
(A) Schematic diagram summarizing features of
adult-onset and juvenile HD pathology.
(B) H&E staining in control, adult-onset, and juve-
nile-onset HD cases with cerebellar atrophy.
(C) a-polyGln, a-polySer, a-polyCys and
a-IBA1staining in cerebellar layers.
(D) Quantitation of IHC-positive cells with 1C2
(polyGln) and a-polySer-Ct, a-polyCys-Ct, and
a-IBA1 antibodies.WM,whitematter; GCL, granule
cell layer; PCL, Purkinje-cell layer; ML, molecular
layer. Red, positive staining; blue, nuclear coun-
terstain. Staining of cerebellum in adult-onset HD
cases is variable. IHC images and quantification of
percent positive cells represent typical positive
regions. See also Figures S5A and S5B.regions included molecular layer interneurons, Bergmann glia
and basket cells surrounding the Purkinje cells, the granular layer
and subcortical and deep white matter regions including regions
surrounding the dentate nuclei (Figure 5C, S5A, and S5B). Addi-
tionally, RAN protein staining in the white matter surrounding the
dentate nucleus was found in regions of gliosis, with prominent
a-polyCys staining of astrocytes andmicroglia-like cells (Figures
S5A and S5B). A second juvenile case (JHD-2), also with cere-
bellar atrophy, showed polySer- and polyCys-positive staining
in similar regions as well as in the remaining Purkinje cells (Fig-
ure S5A). In contrast, polyglutamine staining in the cerebellum
was rare in all cases, with no positive staining detected in the
adult-onset cases or JHD-2 using the 1C2 or EM48 antibodies
(Figures 5C and S5A), and few positive cells per 203 field in
JHD-1 detected with 1C2 but not EM48 (Figure S5A).
Similar to the results obtained in the adult-onset HD striatum
(Figure 2), IBA1 staining of juvenile HD cerebella showed abun-
dant microglial-like cells in regions strongly positive for HD-RAN
polySer and polyCys. Microglia/monocyte staining mostly dis-674 Neuron 88, 667–677, November 18, 2015 ª2015 Elsevier Inc.played a ramified morphology in the adult
and less affected juvenile cerebellum. In
contrast, IBA1-positive cells were more
abundant in the severely affected juvenile
cerebellum and displayed active, round
amoeboid morphology, with a similar dis-
tribution pattern to that observed for
a-polySer and a-polyCys staining (Figures
5C and S5A). These results show high
levels of RAN protein accumulation in
severely affected regions with minimal
polyGln staining.
DISCUSSION
Our understanding of HD has been built
on studying the effects of the AUG-initi-
ated polyGln expansion protein. In this
report, we provide evidence that addi-
tional expansion proteins, polyAla, poly-
Ser, polyLeu, and polyCys, are ex-pressed; accumulate in HD patient brains; and contribute to
disease pathology. First, HD-RAN proteins show abundant pos-
itive staining in regions of the brain most affected by HD,
including the caudate/putamen and, in juvenile-onset cases,
also the cerebellum. Second, regions with intense RAN-positive
staining show pathologic features of HD, including activated
caspase-3 staining, activatedmicroglia, and gliosis. Third, prom-
inent RAN-positive staining was observed in the absence of
detectable polyGln (Herndon et al., 2009) staining in several
white matter regions, suggesting RAN proteins play a role in
HD white matter abnormalities (Bohanna et al., 2011; Fen-
nema-Notestine et al., 2004; Paulsen et al., 2010; Reading
et al., 2005). Fourth, in vitro studies indicate that HD-RAN pro-
teins are toxic to neural cells. Fifth, increased polyAla accumula-
tion and aggregation of polySer RAN proteins occurs in cells
expressing longer repeats >52, which are typically associated
with earlier disease onset andmore severe juvenile HD. Addition-
ally, the accumulation of RAN polySer at 35, but not 23 repeats,
is worth considering as a possible trigger of disease, since 35
Table 2. HD-RAN Protein Staining and Cerebellar Atrophy in
Juvenile HD
Cases JHD Age Repeat PMD CBL Atrophy RAN
1 8 >100*  ++++ ++++
2 8 100*  ++ ++
3 27 69 22 + ++
4 23 76 14 + +
5 23 64 13 + ++
RAN staining: +, low-intensity staining; ++, moderate intensity; +++,
frequent and intense; ++++, highly frequent positive cells with high inten-
sity staining. JHD, juvenile HD. * repeat length estimated from autopsy
brains.repeats is near the threshold at which HD can manifest. Finally,
increased HD-RAN protein staining is found in highly affected
juvenile-onset cerebellar tissue.
It was previously suggested that the CAG expansions can un-
dergo frameshifting that results in the production of fusion pro-
teins that start with an AUG-initiation codon in the glutamine
frame and shift to alternative reading frames to produce hybrid
polyGln/polyAla or polyGln/polySer proteins (Davies and Ru-
binsztein, 2006; Gaspar et al., 2000; Stochmanski et al., 2012;
Toulouse et al., 2005). Here we demonstrate that neither frame-
shifting nor an AUG initiation codon is required for the expression
of polyAla or polySer and that both sense and antisense HD-RAN
proteins are abundantly expressed in affected regions of HD
autopsy brains. (Figure 1 and S1Ac). While the detection of
HD-RAN proteins with C-terminal antibodies demonstrates that
these proteins include C-terminal flanking sequences, future
studies will be important to characterize their specific initiation
and termination sites. Additionally, it will be important to deter-
mine the stability and aggregation properties of these proteins
as well as the mechanisms of protein clearance.
Thediscovery thatRANproteinsareexpressedandaccumulate
at sites of HD pathology provides new insights that may explain
the selective vulnerability of the caudate/putamen in adult-onset
cases and the variability of affected regions of the brain in juve-
nile-onset HD. First, RAN proteins are frequently found in cells
expressing active-caspase-3, including in white-matter-bundle
regions that show RAN but not HTT-polyGln accumulation. Addi-
tionally, the observation that 40%–50% of IBA1 cells are also
RAN-positive suggests microglia/macrophages are recruited to
RAN-positive regions and engulf RAN proteins or RAN-positive
cells. Alternatively, it is possible that a subset of microglia/macro-
phages expressRANproteins. Taken together, these results raise
the possibility that HD-RAN proteins trigger neuroinflammatory
changes (Bjo¨rkqvist et al., 2008, 2009; Myers et al., 1991; Pavese
et al., 2006; Tai et al., 2007) and cell death in HD.
As recently described, cerebellar atrophy has been reported in
both adult and juvenile HD cases (Nance et al., 1999; Ru¨b et al.,
2013; Seneca et al., 2004) and may contribute to balance,
speech, and gait problems found in HD patients (Koller and Trim-
ble, 1985; Margolis and Ross, 2003; Ru¨b et al., 2013). The pref-
erential accumulation of HD-RAN versus HD-polyGln proteins in
the cerebellum (Figures 3, 5, and S5; Table 1) in both adult and
juvenile cases suggests the possibility that RAN proteins triggerthe neurodegeneration seen in juvenile cases (Table 2) and may
also cause functional problems in adults.
It is striking that RAN but not polyGln proteins accumulate in
white matter regions of the striatum, frontal cortex, and cere-
bellum. These data suggest several possibilities that may
explain the region-specific accumulation of HD-RAN proteins:
(1) the shorter RAN proteins may be more aggregate prone
and easier to detect than HTT-polyGln, (2) degradation path-
ways may less efficiently target RAN proteins leading to their
preferential accumulation, and (3) RAN translation may be
more efficient in specific cell types. Additional research will
be required to determine if the accumulation of RAN proteins
in specific white matter regions underlies the early white matter
abnormalities seen by diffusion tensor imaging in HD patients
(Rosas et al., 2006; Ru¨b et al., 2013) and cause early signs of
the disease.
While additional work will be required to sort out the contribu-
tions of HD-RAN proteins in disease, two mouse models that
show HD-like phenotypes were developed using a mixed CAG/
CAA repeat encoding a polyGln tract (Gray et al., 2008; O’Brien
et al., 2015). While these animals express a polyGln expansion
across the CAG/CAA repeat, the CAG/CAA mixed repeat is
also predicted to form a complex hairpin-containing structure
that may also produce two novel di-peptide (Thr/Ala and Asn/
Ser) RAN proteins, which may contribute to the phenotypes
found in thesemodels. Additional animal models that allow direct
comparisons of the effects of polyGln, individual RAN proteins
and sense and antisense RNAs will be required to fully under-
stand how each of these CAG,CTG expansion mutation prod-
ucts contributes to disease.
Although additional work will be needed to understand the in-
dividual and combined effects of HD-RAN proteins, it is possible
that one or more of these proteins is highly toxic and that strate-
gies to target or increase turnover of selected proteins may miti-
gate disease (Cleary and Ranum, 2014). It may also be possible
to downregulate RAN translation without inhibiting canonical
AUG-initiated translation and that decreasing overall RAN pro-
tein load will have beneficial effects (Cleary and Ranum, 2014).
Alternatively, targeting the HTT sense transcript using antisense
oligonucleotides has been described as a promising therapeutic
approach for HD (Hu et al., 2012; Kordasiewicz et al., 2012).
While preclinical strategies to target the HD sense RNAs, as
well as other therapeutic approaches (Lee et al., 2013; Menalled
and Brunner, 2014; Switonski et al., 2012), are promising, it will
be important to determine which of these mouse models accu-
rately reproduce the sense and antisense expression seen in hu-
mans and to correlate these findings with the recovery seen in
each of the models studied.
In summary, the accumulation of both sense and antisense
RAN proteins in human autopsy brains and their toxicity sug-
gests strategies targeting both transcripts may be required to
effectively treat disease in humans. Additionally, HD-RAN pro-
teins may prove to be useful biomarkers to predict disease onset
and progression and responses to future therapeutic treatments.
Finally, the discovery that RAN translation can occur when an
expansion mutation is located in an ORF raises the possibility
that RAN proteins also contribute to eight other CAG polyglut-
amine expansion disorders.Neuron 88, 667–677, November 18, 2015 ª2015 Elsevier Inc. 675
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